Activity of oxiracetam in patients with organic brain
syndrome: a neuropsychological study.
Moglia A, Sinforiani E, Zandrini C, Gualtieri S, Corsico R, Arrigo A
Clin Neuropharmacol 1986;9 Suppl 3:S73-8
ABSTRACT
Oxiracetam is a new psychotropic
drug that has been shown to positively affect processes both in animals and in
patients with impaired brain function. The aim of this study was the
evaluation of the effects of oxiracetam treatment on clinical symptoms in 43
patients with organic brain syndrome (OBS). After a 2-week washout period,
patients were assigned to either oxiracetam or placebo, according to a
randomized, double-blind, between-patients design. Both oxiracetam and placebo
were orally given bid for 8 weeks; daily dose of oxiracetam was 2 X 800 mg. In
OBS patients with a mild to moderate degree of cognitive impairment,
oxiracetam showed to improve cognitive functions, logical performance, and
attention. Other behavioral and functional parameters were also positively
modified.